IntroductIon
Antiphospholipid syndrome (APS) is a quite frequent etiology of acquired thrombophilia. It is characterized by venous or arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid antibodies (aPL) (lupus anticoagulant, anticardiolipin antibodies and/or anti-b2GP1). 1 It can be associated with either auto-immune diseases such as systemic lupus erythematosus (SLE) or neoplasms, infections or drugs. Clinical manifestations are various. Deep venous thrombosis is the most frequently reported manifestation. 2 Arterial thromboses are frequently located into the brain and can be associated with venous thromboses. Obstetrical complications include fetal losses, premature births and preeclampsia. Catastrophic APS (CAPS) is a rare (<1%) but lifethreatening presentation, characterized by multiple small vessel thromboses that can lead to multi-organ failure. 3 Our patient was diagnosed an atypical left hydronephrosis associated with acute renal failure while he was treated with oral vitamin K antagonists (VKA) and aspirin. The final diagnosis, histologically proven, was a left ureteral ischemia due to distal arterial and venous thromboses, associated with glomeruli lesions. To our knowledge, it is the first description of such a thrombosis localisation in APS. 
case report

AbstrAct
Urinary tract involvement is rarely described in antiphospholipid syndrome (APS). We report the case of a 40 year-old man with primitive APS who developed an arterial and venous unilateral ureteral ischemia revealed by painful unilateral hydronephrosis. The patient was on oral anticoagulation for six years because of two deep venous thromboses. He developed then a massive splenic infarct and an acute myocardial infarct, which required the intensification of his anticoagulation and high doses of corticosteroids. Three months later, he was explored for a latero-thoracic pain. Biology found an acute renal failure and microscopic haematuria. CT scan showed a hypoperfusion of the left kidney, an ostial defect on renal artery and a left hydronephrosis. Retrograde pyelography found a stenosis of the proximal ureter. A dilatation with stenting failed, leading to a partial left ureteral resection. Histology confirmed ureteral segmental organized arterial thrombosis and venous thrombosis. Evolution was favourable with stabilization of creatinine. A retrograde ureteropyelography was then performed, showing a tight stenosis of the left proximal ureter on four cm. It was impossible to insert an endoureteral prosthesis. Finally, the patient underwent a surgery: the pathologic ureteral portion was sectioned and an anastomosis was performed. Macroscopically, the ureteral tissue was fibrous and calcified.
Microscopically, there were peri-vascular inflammatory changes, thrombotic and calcified arteries and veins, inside fibro-collagen tissue, and glomerular lesions (figure 2). We conclude that it was a semi-recent both arterial and venous ureteral thrombosis, which had probably happened on September 2008 and hadn't been diagnosed then.
The glomerular lesions associated with acute renal failure, which was persistent despite urine surgical derivation, were considered as the proof of microvascular involvement. The patient was discharged after a few days, with maintenance of the same anticoagulant treatment. Renal function stabilized with a creatinine of 115µmol/l (Cockroft-Gault clearance = 80 ml/min).
Discussion
Urinary tract involvement is rarely described in APS. In SLE, chronic interstitial cystitis and secondary ureteral stenosis have occasionally been described, mostly associated with gastrointestinal symptoms (lupus enteropathy). 4 We present here the first case of arterial and venous unilateral ureteral ischemia presenting as a hydronephrosis in a patient with APS.
Renal lesions include thrombotic microangiopathy lesions, which can be acute or chronic, and affect intra-parenchymatous arterioles and glomerular capillaries. Renal artery thrombosis is less frequent and can lead to renal infarct or reno-vascular hypertension. Our patient developed an acute renal failure without hypertension, probably due to minimal renal thrombotic microangiopathy.
CAPS or Asherson's syndrome is the worst manifestation of APS. Its mortality rate is up to 40 %. 5 It is defined as three or more simultaneous new thromboses in different organs/systems/ tissues, with histological confirmation of microvascular involvement and aPL detection. Our patient presented a CAPS, histologically proven, successfully managed with high-dose corticosteroids and intensification of anticoagulation.
It has been proven that lupus anticoagulant was the biological test for APL detection the most associated with venous thromboses (risk ratio of 6 versus 2 with the other APL antibodies). 6 Our patient had a lupus anticoagulant.
Treatment of thrombotic manifestations in APS is based on anticoagulation and platelet antiaggregants. There is a consensus to treat a first venous thrombosis in patients with APS with prolonged oral anticoagulation and an INR between 2 and 3. If thrombosis recurs under VKA or if it is an arterial thrombosis, the target INR is commonly risen to > 3 and antiaggregants are added.
CAPS is treated with high doses of intravenous unfractionned heparin and corticosteroids. In the life-threatening cases, plasmatic exchanges or intravenous immunoglobulins are added to lower plasmatic aPL rate. Indeed, it has been demonstrated that aPL were indirectly pathogenic by binding to phospholipid-binding plasma b2 glycoprotein I. Anti-domain I antibodies seem to be the most uniformly correlated with occurrence of thrombosis. 7 Research on anti-I antibodies biological properties have found numerous ways of action on haemostasis: antibodies increase resistance against annexin 5, 8 then countering its anticoagulant properties; they inhibit the anticoagulant properties of protein C, 9 independently of Factor V Leiden, and they increase concentration of activated Von Willebrand Factor. LDL receptors also have a crucial role in generating thrombosis: it was shown that antibodybound b2GP1 could bind and activate platelets through LDLreceptor-related protein. 10 Moreover, APS is now described as an inflammatory pro-thrombotic disorder, as aPL are able to activate cellular elements (platelets, endothelial cells and monocytes), inhibit the fibrinolytic system, activate the coagulation cascade and activate the complement system. 
